<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026831</url>
  </required_header>
  <id_info>
    <org_study_id>2452-001</org_study_id>
    <secondary_id>2009_701</secondary_id>
    <nct_id>NCT01026831</nct_id>
  </id_info>
  <brief_title>Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)</brief_title>
  <official_title>A Phase III, Randomized, Active Comparator-Controlled, Twelve-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma and Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to compare the safety and efficacy of the preservative-free formulation of
      0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with
      open-angle glaucoma and ocular hypertension. This study was to demonstrate that the
      preservative-free formulation of 0.0015% tafluprost is non-inferior to preservative-free 0.5%
      timolol maleate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2010</start_date>
  <completion_date type="Actual">September 17, 2010</completion_date>
  <primary_completion_date type="Actual">September 17, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure (IOP) Change From Baseline at All 9 Time Points During the Study (0800, 1000 and 1600 Hrs at Weeks 2, 6, and 12)</measure>
    <time_frame>Baseline, Weeks 2, 6, and 12.</time_frame>
    <description>IOP was measured using a Goldmann applanation tonometer. The primary evaluation was based on the study eye (the worse eye based on the 0800 hour IOP baseline or the right eye when both eyes had the same IOP).
IOP change from baseline was calculated using the baseline IOP at each time point (0800 hours at baseline to 0800 hours at Week 2, 6, and 12; 1000 hours at baseline to 1000 hours at Week 2, 6, and 12; 1600 hours at baseline to 1600 hours at Week 2, 6, and 12).
Lowering elevated IOP is a treatment goal of glaucoma.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Baseline IOP</measure>
    <time_frame>Baseline</time_frame>
    <description>IOP was measured using a Goldmann applanation tonometer. The primary evaluation was based on the study eye (the worse eye based on the 0800 hour IOP baseline or the right eye when both eyes had the same IOP).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">643</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Tafluprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preservative-free tafluprost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>timolol maleate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preservative-free timolol maleate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative-Free Tafluprost</intervention_name>
    <description>One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks</description>
    <arm_group_label>Tafluprost</arm_group_label>
    <other_name>MK2452</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: timolol</intervention_name>
    <description>One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks</description>
    <arm_group_label>timolol maleate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been diagnosed with primary open-angle glaucoma, pigmentary glaucoma,
             capsular glaucoma/pseudoexfoliation, or ocular hypertension

          -  Patient has a mean (or median) IOP of &gt;=23 and =&lt;36 in at least one eye at the 0800
             hours time point at the Baseline Visit.

          -  Patient has &lt;5 mmHg difference in mean (or median) IOP between eyes at each time point
             (0800 hours, 1000 hours, and 1600 hours) at Baseline.

          -  Patient is currently using a prescribed ocular hypotensive medication and has been on
             a stable dose for 30 days prior to screening, or patient is drug-naive (those who have
             never used or who have not used ocular hypotensive medication for at least 4 weeks
             prior to screening)

          -  Patient is able to safely discontinue current ocular hypotensive medication during up
             to the 4-week washout period

          -  Patient has vision corrected to 20/80 or better in each eye

          -  Patient is willing and able to avoid wearing contact lenses from 4 weeks prior to
             dosing through 24 hour after final dosing

          -  Patient is willing and able to self-administer or has an able person available on a
             daily basis to assist with administration of study medications

          -  Patient is not pregnant and not planning to become pregnant during the study

          -  Patient is male or female ≥18 of age on the day of signing the informed consent

        Exclusion Criteria:

          -  Patient is unable to use study medication in the affected eye(s)

          -  Patient has a history of inflammatory ocular surface disease or anterior or posterior
             uveitis in either eye

          -  Patient has a history of retinal detachment, diabetic retinopathy, or other
             progressive retinal disease

          -  Patient has experienced significant visual field loss within the last year

          -  Patient has had intraocular surgery in either eye in the last 4 months

          -  Patient has a history of glaucoma surgery or refractive surgery in either eye

          -  Patient is currently taking two or more anti-glaucoma medications (except Cosopt™ or
             its generic formulation)

          -  Patient has previously used tafluprost

          -  Patient has a history of cardiovascular disorder within 6 months prior to screening

          -  Patient has a history of bronchial asthma, wheezing, pneumonia, COPD, other pulmonary
             disease, or abnormal chest x-ray

          -  Patient has a mean (or median) IOP &gt;36 mmHg in either eye at the Screening Visit or at
             any time point (0800 hours, 1000 hours, and 1600 hours) of the Baseline Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>August 9, 2011</results_first_submitted>
  <results_first_submitted_qc>August 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2011</results_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tafluprost</title>
          <description>One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Timolol Maleate</title>
          <description>One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="320">randomized</participants>
                <participants group_id="P2" count="323">randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tafluprost</title>
          <description>One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Timolol Maleate</title>
          <description>One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="320"/>
            <count group_id="B2" value="323"/>
            <count group_id="B3" value="643"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="11.7"/>
                    <measurement group_id="B2" value="63.3" spread="11.6"/>
                    <measurement group_id="B3" value="63.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Intraocular Pressure (IOP) Change From Baseline at All 9 Time Points During the Study (0800, 1000 and 1600 Hrs at Weeks 2, 6, and 12)</title>
        <description>IOP was measured using a Goldmann applanation tonometer. The primary evaluation was based on the study eye (the worse eye based on the 0800 hour IOP baseline or the right eye when both eyes had the same IOP).
IOP change from baseline was calculated using the baseline IOP at each time point (0800 hours at baseline to 0800 hours at Week 2, 6, and 12; 1000 hours at baseline to 1000 hours at Week 2, 6, and 12; 1600 hours at baseline to 1600 hours at Week 2, 6, and 12).
Lowering elevated IOP is a treatment goal of glaucoma.</description>
        <time_frame>Baseline, Weeks 2, 6, and 12.</time_frame>
        <population>The Per-Protocol (PP) approach excluded all patients with important protocol violations and was performed for the efficacy endpoints. The PP population excluded patients due to important deviations from the protocol that may have substantially affected the results of the primary endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Tafluprost</title>
            <description>One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate</title>
            <description>One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intraocular Pressure (IOP) Change From Baseline at All 9 Time Points During the Study (0800, 1000 and 1600 Hrs at Weeks 2, 6, and 12)</title>
          <description>IOP was measured using a Goldmann applanation tonometer. The primary evaluation was based on the study eye (the worse eye based on the 0800 hour IOP baseline or the right eye when both eyes had the same IOP).
IOP change from baseline was calculated using the baseline IOP at each time point (0800 hours at baseline to 0800 hours at Week 2, 6, and 12; 1000 hours at baseline to 1000 hours at Week 2, 6, and 12; 1600 hours at baseline to 1600 hours at Week 2, 6, and 12).
Lowering elevated IOP is a treatment goal of glaucoma.</description>
          <population>The Per-Protocol (PP) approach excluded all patients with important protocol violations and was performed for the efficacy endpoints. The PP population excluded patients due to important deviations from the protocol that may have substantially affected the results of the primary endpoints.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 - 0800 (n=280; n=295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" lower_limit="-7.5" upper_limit="-6.8"/>
                    <measurement group_id="O2" value="-6.8" lower_limit="-7.1" upper_limit="-6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 - 1000 (n=293; n=305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" lower_limit="-7.1" upper_limit="-6.5"/>
                    <measurement group_id="O2" value="-6.1" lower_limit="-6.4" upper_limit="-5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 - 1600 (n=289; n=302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" lower_limit="-6.5" upper_limit="-5.9"/>
                    <measurement group_id="O2" value="-5.3" lower_limit="-5.7" upper_limit="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 - 0800 (n=294; n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" lower_limit="-7.6" upper_limit="-6.9"/>
                    <measurement group_id="O2" value="-7.4" lower_limit="-7.7" upper_limit="-7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 - 1000 (n=298; n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-7.3" upper_limit="-6.7"/>
                    <measurement group_id="O2" value="-6.6" lower_limit="-6.9" upper_limit="-6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 - 1600 (n=295; n=310)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" lower_limit="-6.7" upper_limit="-6.0"/>
                    <measurement group_id="O2" value="-5.5" lower_limit="-5.9" upper_limit="-5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 0800 (n=296; n=308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" lower_limit="-7.8" upper_limit="-7.1"/>
                    <measurement group_id="O2" value="-7.5" lower_limit="-7.8" upper_limit="-7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 1000 (n=298; n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-7.4" upper_limit="-6.7"/>
                    <measurement group_id="O2" value="-6.6" lower_limit="-7.0" upper_limit="-6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 1600 (n=295; n=310)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" lower_limit="-6.5" upper_limit="-5.9"/>
                    <measurement group_id="O2" value="-5.7" lower_limit="-6.0" upper_limit="-5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline IOP</title>
        <description>IOP was measured using a Goldmann applanation tonometer. The primary evaluation was based on the study eye (the worse eye based on the 0800 hour IOP baseline or the right eye when both eyes had the same IOP).</description>
        <time_frame>Baseline</time_frame>
        <population>The Per-Protocol (PP) approach excluded all patients with important protocol violations and was performed for the efficacy endpoints. The PP population excluded patients due to important deviations from the protocol that may have substantially affected the results of the primary endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Tafluprost</title>
            <description>One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate</title>
            <description>One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline IOP</title>
          <description>IOP was measured using a Goldmann applanation tonometer. The primary evaluation was based on the study eye (the worse eye based on the 0800 hour IOP baseline or the right eye when both eyes had the same IOP).</description>
          <population>The Per-Protocol (PP) approach excluded all patients with important protocol violations and was performed for the efficacy endpoints. The PP population excluded patients due to important deviations from the protocol that may have substantially affected the results of the primary endpoints.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 0800 timepoint (n=299; n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="25.8" upper_limit="26.4"/>
                    <measurement group_id="O2" value="26.0" lower_limit="25.7" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 1000 timepoint (n=299; n=313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="24.5" upper_limit="25.2"/>
                    <measurement group_id="O2" value="24.6" lower_limit="24.2" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 1600 timepoint (n=296; n=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="23.4" upper_limit="24.2"/>
                    <measurement group_id="O2" value="23.5" lower_limit="23.2" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tafluprost</title>
          <description>One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Timolol Maleate</title>
          <description>One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

